文献速递脑血管病

脑出血后早期恢复抗血小板治疗与大出血风险

Early Antiplatelet Resumption and the Risks of Major Bleeding After Intracerebral Hemorrhage.
PubMed 文献 · Stroke · 2023-01-09

基于台湾全民健康保险研究数据库2008至2017年1584例脑出血存活者,按恢复抗血小板时机分为早期(≤30天)与晚期(31-365天)组,匹配后两组1年复发性脑出血风险相似(3.12% vs 3.27%;AHR 0.967,95%CI 0.522-1.791),早期恢复与延迟恢复同样安全。

要点

  • 脑出血后早期(≤30天)恢复抗血小板与晚期恢复的1年复发性脑出血风险相似。
  • 无既往脑血管病患者早期恢复抗血小板与较低的全因死亡和大出血事件风险相关。
  • 慢性肾病患者早期恢复抗血小板与较低的缺血性卒中风险相关。

核心结论

  • 在脑出血患者中,早期恢复抗血小板与延迟恢复抗血小板同样安全。
  • 无既往脑血管病或合并慢性肾脏病的患者可能从早期恢复抗血小板中获益更多。

研究设计与样本

  • 基于台湾全民健康保险研究数据库2008至2017年的脑出血患者数据。
  • 筛选脑出血前及恢复抗血小板后药物持有率≥50%的患者,排除心房颤动、心力衰竭、接受抗凝或血液透析治疗、以及恢复抗血小板前发生脑血管事件或死亡者。
  • 最终纳入1584例符合条件的患者,按恢复抗血小板时机分为早期组(≤30天)和晚期组(31-365天)。
  • 随访至临床结局发生、1年随访结束、死亡或2018年12月31日。
  • 采用匹配后Cox比例风险模型比较两组。

主要发现

  • 匹配后两组1年复发性脑出血风险相似(早期组3.12% vs 晚期组3.27%;AHR 0.967,95%CI 0.522-1.791)。
  • 两组1年随访时各次要结局风险也相似。
  • 亚组分析显示,无既往脑血管病患者早期恢复抗血小板与较低的全因死亡风险相关(AHR 0.199,95%CI 0.054-0.739)和较低的大出血事件风险相关(AHR 0.090,95%CI 0.010-0.797)。
  • 合并慢性肾脏病患者早期恢复抗血小板与较低的缺血性卒中风险相关(AHR 0.065,95%CI 0.012-0.364)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The appropriate timing of resuming antithrombotic therapy after intracerebral hemorrhage (ICH) remains unclear. The aim of this study was to compare the risks of major bleeding between early and late antiplatelet resumption in ICH survivors. METHODS: Between 2008 and 2017, ICH patients were available in the National Health Insurance Research Database. Patients with a medication possession ratio of antiplatelet treatment ≥50% before ICH and after antiplatelet resumption were screened. We excluded patients with atrial fibrillation, heart failure, under anticoagulant or hemodialysis treatment, and developed cerebrovascular events or died before antiplatelet resumption. Finally, 1584 eligible patients were divided into EARLY (≤30 days) and LATE groups (31-365 days after the index ICH) based on the timing of antiplatelet resumption. Patients were followed until the occurrence of a clinical outcome, end of 1-year follow-up, death, or until December 31, 2018. The primary outcome was recurrent ICH. The secondary outcomes included all-cause mortality, major hemorrhagic events, major occlusive vascular events, and ischemic stroke. Cox proportional hazard model after matching was used for comparison between the 2 groups. RESULTS: Both the EARLY and LATE groups had a similar risk of 1-year recurrent ICH (EARLY versus LATE: 3.12% versus 3.27%; adjusted hazard ratio [AHR], 0.967 [95% CI, 0.522-1.791]) after matching. Both groups also had a similar risk of each secondary outcome at 1-year follow-up. Subgroup analyses disclosed early antiplatelet resumption in the patients without prior cerebrovascular disease were associated with lower risks of all-cause mortality (AHR, 0.199 [95% CI, 0.054-0.739]) and major hemorrhagic events (AHR, 0.090 [95% CI, 0.010-0.797]), while early antiplatelet resumption in the patients with chronic kidney disease were associated with a lower risk of ischemic stroke (AHR, 0.065 [95% CI, 0.012-0.364]). CONCLUSIONS: Early resumption of antiplatelet was as safe as delayed antiplatelet resumption in ICH patients. Besides, those without prior cerebrovascular disease or with chronic kidney disease may benefit more from early antiplatelet resumption.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Liu CH, Wu YL, Hsu CC, et al. Early Antiplatelet Resumption and the Risks of Major Bleeding After Intracerebral Hemorrhage. Stroke. 2023. PMID: 36621820. doi:10.1161/STROKEAHA.122.040500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。